BR0316021A - Comibinação compreendendo um inibidor de cdk e cisplatina - Google Patents

Comibinação compreendendo um inibidor de cdk e cisplatina

Info

Publication number
BR0316021A
BR0316021A BR0316021-1A BR0316021A BR0316021A BR 0316021 A BR0316021 A BR 0316021A BR 0316021 A BR0316021 A BR 0316021A BR 0316021 A BR0316021 A BR 0316021A
Authority
BR
Brazil
Prior art keywords
cdk
inhibitor
cisplatin
combination
relates
Prior art date
Application number
BR0316021-1A
Other languages
English (en)
Inventor
Athos Giannella-Borradori
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0225874A external-priority patent/GB0225874D0/en
Priority claimed from GB0300293A external-priority patent/GB0300293D0/en
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of BR0316021A publication Critical patent/BR0316021A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçãO COMPREENDENDO UM INIBIDOR DE CDK E CISPLATINA". Um primeiro aspecto da invenção refere-se a uma combinação compreendendo um inibidor de CDK e cisplatina. Um segundo aspecto da invenção refere-se a um produto farmacêutico compreendendo um inibidor de CDK e cisplatina como uma preparação combinada para uso simultâneo, seq³encial ou separado em terapia. Um terceiro aspecto da invenção refere-se a um método de tratamento de um distúrbio proliferativo, o dito método compreendendo simultaneamente, seq³encialmente ou separadamente administrar um inibidor de CDK e cisplatina a um indivíduo.
BR0316021-1A 2002-11-06 2003-11-05 Comibinação compreendendo um inibidor de cdk e cisplatina BR0316021A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0225874A GB0225874D0 (en) 2002-11-06 2002-11-06 Combination
GB0300293A GB0300293D0 (en) 2003-01-07 2003-01-07 Combination
PCT/GB2003/004773 WO2004041267A1 (en) 2002-11-06 2003-11-05 Combination comprising a cdk inhibitor and cisplatin

Publications (1)

Publication Number Publication Date
BR0316021A true BR0316021A (pt) 2005-09-27

Family

ID=32313984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316021-1A BR0316021A (pt) 2002-11-06 2003-11-05 Comibinação compreendendo um inibidor de cdk e cisplatina

Country Status (8)

Country Link
US (1) US20050276866A1 (pt)
EP (1) EP1558239A1 (pt)
JP (1) JP2006508185A (pt)
AU (1) AU2003276463A1 (pt)
BR (1) BR0316021A (pt)
CA (1) CA2502969A1 (pt)
MX (1) MXPA05004920A (pt)
WO (1) WO2004041267A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
DE60325502D1 (de) * 2002-11-06 2009-02-05 Cyclacel Ltd Kombination aus docetaxel und einem cdk-hemmer
US20060136741A1 (en) * 2004-12-16 2006-06-22 Saflink Corporation Two factor token identification
CN102223885B (zh) 2008-11-24 2013-04-03 内尔维阿诺医学科学有限公司 用于治疗间皮瘤的cdk抑制剂
JP2015510910A (ja) * 2012-03-21 2015-04-13 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 特定の腫瘍の処置のための、（ｒｓ）−ｓ−シクロプロピル−ｓ−（４−｛［４−｛［（１ｒ，２ｒ）−２−ヒドロキシ−１−メチルプロピル］オキシ｝−５−（トリフルオロメチル）ピリミジン−２−イル］アミノ｝フェニル）スルホキシミドの使用
US9872874B2 (en) 2012-05-15 2018-01-23 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6849631B2 (en) * 2000-12-08 2005-02-01 Bristol Myers Squibb Pharma Company Semicarbazides and their uses

Also Published As

Publication number Publication date
MXPA05004920A (es) 2005-08-18
US20050276866A1 (en) 2005-12-15
CA2502969A1 (en) 2004-05-21
AU2003276463A1 (en) 2004-06-07
EP1558239A1 (en) 2005-08-03
WO2004041267A1 (en) 2004-05-21
JP2006508185A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
BR0316004A (pt) Composição farmacêutica compreendendo um inibidor de cdk e gemcitabina
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
BRPI0519195A2 (pt) composiÇço de cuidado oral, e, mÉtodo para prevenir ou tratar cÁrie dental em um indivÍduo humano ou animal
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
HK1071310A1 (en) Combination therapy for the treatment of cancer
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
BR0108728A (pt) Combinação farmacêutica terapêutica, e, método para tratar um c ncer.
ATE504303T1 (de) Kombination aus roscovitine und cs-682 oder seinem metaboliten cndac
NO20064753L (no) Kombinasjonsterapi
BR0316021A (pt) Comibinação compreendendo um inibidor de cdk e cisplatina
BR0316029A (pt) Combinação
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
BRPI0804070A2 (pt) usos do domìnio intracitoplasmático da proteìna da quinase de linfoma anaplástico e de uma molécula de ácido nucleico, e, produto
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
PL368686A1 (en) Novel aminobenzoephenones
BR0316010A (pt) Combinação
ATE294585T1 (de) Vorbeugung von kolorektalkrebs
BR0308756A (pt) Combinação compreendendo um inibidor de cdk e doxorrubicina
MXPA04009012A (es) Combinacion de inhibidor ofa cdk y 5 fu para el tratamiento de cancer.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]